<DOC>
	<DOCNO>NCT00303901</DOCNO>
	<brief_summary>RATIONALE : Cryotherapy kill tumor cell freeze . This may effective treatment primary lung cancer lung metastases remove surgery . PURPOSE : This clinical trial study well cryotherapy work treat patient primary lung cancer lung metastases remove surgery .</brief_summary>
	<brief_title>Cryotherapy Treating Patients With Primary Lung Cancer Lung Metastases That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Estimate local distant failure rate percutaneous thoracic cryotherapy ( PTC ) patient unresectable primary lung cancer lung metastasis . - Estimate rate PTC complication adverse reaction . - Determine correlation procedural parameter follow-up image parameter , latter use surrogates local and/or distant treatment failure . OUTLINE : Patients undergo CT-guided percutaneous thoracic cryotherapy 2 hour local general anesthesia . Grouped cryoprobes insert tumor , utilize freeze-thaw-freeze cycle , create cytotoxic temperature ( less -20°C -40°C ) encompass entire anticipated tumor volume . Patients undergo positron emission tomography baseline cryotherapy assess tumor standard uptake variable . After completion study treatment , patient follow 1 , 3 , 6 12 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant pulmonary neoplasm New lung lesion ( ) definitive clinical imaging feature primary metastatic disease allow Imaging finding compatible localized treatment failure prior cryotherapy allow Malignant pleural effusion allow provide associate distinct measurable pulmonary mass amenable cryotherapy Metastatic disease must meet following criterion : Primary tumor resect deem controlled therapy No widespread metastasis evident ( e.g. , multiple hepatic brain metastasis ) Each pulmonary mass must amenable CTguided percutaneous cryotherapy approach No 5 target mass study therapy Target mass define pulmonary , hilar , mediastinal , and/or chest wall mass &gt; 1 cm , &lt; 10 cm average diameter Unresectable disease surgical consultation OR patient refuse surgical option Nonenhanced enhance CT scan require within past 6 week do 45 mm increment available soft tissue mediastinal window assess size extent thoracic tumor PET scan require within past 6 month note correlation CT location , already obtain combine PET/CT scanner PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) &gt; 60100 % OR WHO/ECOG/Zubrod PS 02 FEV_1 &gt; 30 % predict DLCO &gt; 40 % predict Platelet count ≥ 70,000/mm^3 INR &lt; 1.5 No uncontrolled coagulopathy bleed diathesis Not pregnant nursing Negative pregnancy test No serious medical illness , include follow : Uncontrolled congestive heart failure Uncontrolled angina Myocardial infarction Cerebrovascular event within 6 month prior study entry No medical contraindication potential problem would preclude study compliance PRIOR CONCURRENT THERAPY : At least 7 day since prior aspirin aspirinlike medication At least 3 day since prior warfarin , clopidogrel bisulfate , similar compound No concurrent drug cause bleeding tendency ( e.g. , aspirin , warfarin , clopidogrel bisulfate ) No concurrent participation experimental study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>lung metastasis</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
</DOC>